Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Aggression × vandetanib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 15 Neoplasm Metastasis 10 Carcinoma, Medullary 9 Lung Neoplasms 8 Thyroid Neoplasms 5 Glioblastoma 5 Gliosarcoma 4 Glioma 4 Pancreatic Neoplasms 3 Neoplasms 3 Breast Neoplasms 3 Brain Neoplasms 3 Adenocarcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms 2 Familial medullary thyroid carcinoma 2 Colorectal Neoplasms 2 Carcinoma, Squamous Cell 2 Biliary Tract Neoplasms 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Recurrence 1 Rectal Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

vandetanib 1 selinexor 1 pegfilgrastim 1 midostaurin 1 Topotecan 1 Rituximab 1 Prednisone 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01945762 2024-12-18

Caprelsa104

Sanofi

Aggression, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡